|
Sacramento Díaz-Carrasco M, Ramírez C, Montenegro S, Alonso-Romero JL. [An unexpected and severe infusion reaction induced by trastuzumab]. Farm Hosp. 2014 May 1;38(3):254-5. doi: 10.7399/fh.2014.38.3.1169. Spanish. PubMed PMID: 24951913.
AÑO: 2014
|
|
Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A. Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm. 2015 Dec;37(6):1021-7. doi: 10.1007/s11096-015-0195-z. Epub 2015 Sep 21. PubMed PMID: 26391788.
AÑO: 2015; IF: 2.305
|
|
Sanchez Martinez DA, Canadilla-Ferreira M, Henarejos PS, Alonso Romero JL. Analysis of adolescent oncology cases from 2008 through 2018 in a tertiary-level hospital: an opportunity for improvement. Future Oncol. 2021 Apr;17(12):1545-1551. doi: 10.2217/fon-2020-0475. Epub 2021 Feb 25. PubMed PMID: 33626935.
AÑO: 2021; IF: 3.674
|
|
Bachelot T, Ciruelos E, Schneeweiss A, Puglisi F, Peretz-Yablonski T, Bondarenko I, Paluch-Shimon S, Wardley A, Merot JL, du Toit Y, Easton V, Lindegger N, Miles D; PERUSE investigators. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol. 2019 May 1;30(5):766-773. doi: 10.1093/annonc/mdz061. PubMed PMID: 30796821.
AÑO: 2019; IF: 18.274
|
|
Carballo-Santana, M; Martinez-Garcia, J; Sanchez-Henarejos, P; Ros, S; Marin, M; Marin, G; Garcia-Hernandez, MR; Soto, A; Balsalobre, J; Barcelo, A; Puertes, A; Turrez, E; Jimenez-Lucas, MD; Guirao, M; Cuellar, MA; Cano, A; Martinez-Lacaci, I; Alonso-Romero, JL. Reversal of azd6244 (selumetinib) resistance in primary cultures of colorectal cancer, by p70s6 kinase inhibition using bez-235. EUROPEAN JOURNAL OF CANCER. 2015; 51:S96-S97. 10.1016/S0959-8049(16)30289-1
AÑO: 2015; IF: 7.275
|